A Study of DXC014 in Patients With Advanced Solid Tumors.
Status:
NOT_YET_RECRUITING
Trial end date:
2030-10-20
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.